ESTRO 2024 - Abstract Book

S2277

Clinical - Upper GI

ESTRO 2024

patients (58%) showed a pathological CR (pCR); at the same time, amongst 48 NBD, 35 patients (72.9%) had pCR (p=0.17). There is a statistically significant correlation between UGIE findings and pCR. Out of the 57 patients who had CR in the UGIE, 45 patients had complete pCR, while 12 had residual disease (p=0.001). However, there was no statistically significant correlation between GTV or PTV volumes and pCR rates. Similarly, no meaningful cutoff value for radiation treatment volume could be determined using the Receiver Operating Characteristics (ROC) curve.

Conclusion:

There is no statistically significant difference in the pCR rates between BD and NBD. Hence, the standard CROSS protocol may be extrapolated for its use in BD patients. However, longer follow-up is needed to see its impact on survival.

Keywords: neoadjuvant, chemoradiation, esophageal cancer

3007

Mini-Oral

SABR prior to liver transplantation in HCC patients: a 10 years’ experience

Marzia Cerrato 1 , Silvia Leardi 1 , Ramona Parise 1 , Bruna Lo Zito 1 , Valeria Chiofalo 1 , Damiano Patrono 2 , Fabio Colli 2 , Renato Romagnoli 2 , Patrizia Carucci 3 , Silvia Gaia 3 , Emanuela Rolle 3 , Sara Bartoncini 1 , Giuseppe Carlo Iorio 1 , Serena Badellino 1 , Paolo Ancelliero 1 , Mario Levis 1 , Umberto Ricardi 1 1 University of Turin, Department of Oncology, Turin, Italy. 2 A.O.U. Città della Salute e della Scienza di Torino, Department of Surgical Sciences, General Surgery 2U - Liver Transplant Unit, Turin, Italy. 3 University of Turin, Department of Gastroenterology, Turin, Italy

Purpose/Objective:

Stereotactic ablative radiotherapy (SABR) has emerged as a treatment option in various clinical scenarios for hepatocellular carcinoma (HCC), including the downstaging or bridging role before liver transplantation (LT) in patients in waiting lists. Nowadays it is considered only as an alternative to conventional local ablative therapies when these are not applicable or fail in controlling tumors. To date only limited retrospective case series including few patients are available on this topic. In this study, we investigated the role of SABR either for downstaging or as bridging treatment in patients with HCC awaiting LT and referred to our Institution.

Material/Methods:

We retrospectively analysed data from HCC patients treated with SABR prior to LT between 2012 and 2022. Radiographic response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST). Local control (LC) was defined as the absence of progression. On the explanted liver, the pathologic